Mysoline (Primidone)

Primidone is converted in the liver to phenobarbital, a compound that enhances the activity of the inhibitory neurotransmitter GABA. By increasing GABA‑mediated neuronal inhibition, primidone stabilizes neuronal membranes and diminishes the excessive electrical activity that leads to seizures.

The appropriate dose of Mysoline is individualized by the prescribing clinician based on the patient’s age, weight, seizure type, and response to therapy. Dosage adjustments are made during treatment to achieve optimal seizure control while minimizing side effects.

Safety data for primidone in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and monitoring strategies with their healthcare provider.

To request Mysoline, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Primidone is a barbiturate anticonvulsant that is metabolized to phenobarbital, offering a mechanism distinct from many newer agents such as levetiracetam or lamotrigine. It is often chosen for patients who respond well to phenobarbital‑like activity, but clinicians consider its side‑effect profile and drug‑interaction potential when selecting therapy.

Mysoline should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Mysoline is taken orally, usually in tablet form, with or without food as directed by the prescriber. The exact administration schedule—such as once daily or divided doses—depends on the individual treatment plan and should be followed precisely.

Serious risks include severe skin reactions (e.g., Stevens‑Johnson syndrome), blood disorders like agranulocytosis, significant liver injury, respiratory depression especially when combined with other CNS depressants, and worsening depression or suicidal thoughts. Patients should be monitored closely for any of these signs.

Mysoline is contraindicated in individuals with known hypersensitivity to primidone, phenobarbital, or any barbiturate. Patients with severe hepatic impairment, uncontrolled respiratory disease, or those taking certain interacting medications (e.g., strong CNS depressants) should avoid it unless a specialist determines that benefits outweigh the risks.